Article info
Clinical and epidemiological research
Extended report
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
- Correspondence to Dr Oliver Distler, Division of Rheumatology, University Hospital Zurich, Gloriastr. 25; Zurich 8091, Switzerland; Oliver.Distler{at}usz.ch
Citation
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Publication history
- Received August 29, 2013
- Revised December 12, 2013
- Accepted December 27, 2013
- First published January 17, 2014.
Online issue publication
July 28, 2023
Article Versions
- Previous version (28 July 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions